Immunotherapy for Alzheimer’s disease shows promise in mouse study

Alzheimer’s disease starts with a sticky protein called amyloid beta that builds up into plaques in the brain, setting off a chain of events that results in brain atrophy and cognitive decline. The new generation of Alzheimer’s drugs—the first proven to change the course of the disease—work by tagging amyloid for clearance by the brain’s immune cells.

This article was originally published on MedicalXpress.com

You may also be interested in:

Read More:

Lawyers Lookup